Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 15/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 10/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.64 |
| ▸ | PPARG | P37231 | 5/20 | 0.60 |
| ▸ | PPARD | Q03181 | 5/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14518660 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL5411629 | 0.87 | ADORA3 (0.76) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL14518654 | 0.87 | ADORA3 (0.76) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL29775232 | 0.78 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2B | |
| SCHEMBL19807555 | 0.78 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2B | |
| SCHEMBL29524240 | 0.78 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2B | |
| SCHEMBL12264931 | 0.78 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2B | |
| SCHEMBL13388266 | 0.78 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2B | |
| SCHEMBL19503865 | 0.78 | ADORA3 (0.76) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL19465000 | 0.78 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199127-B2 | Purine nucleosides | UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-04-03 | — | — | US | claimed |
| US-20050256143-A1 | Purin-9-yl-tetrahydrothiophene-3,4-diols; anticarcinogenic agents selective to A3 adenosine receptors; breast cancer | Government of the United States of America, repres ented by The Secretary, Department of Health and (US) | 2005-11-17 | — | — | US | claimed |
| EP-1578758-A2 | PURINE NUCLEOSIDES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-09-28 | — | — | EP | claimed |
| WO-2004038006-A2 | PURINE NUCLEOSIDES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-05-06 | — | — | WO | claimed |
| US-9668959-B2 | A3 adenosine receptor ligands for modulation of pigmentation | ORADIN PHARMACEUTICAL LTD. (IL) | 2017-06-06 | — | — | US | disclosed |
| EP-2456419-B1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | ORADIN PHARMACEUTICAL LTD (IL) | 2016-11-23 | — | — | EP | disclosed |
| US-20160136079-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | ORADIN PHARMACEUTICAL LTD. (IL) | 2016-05-19 | — | — | US | disclosed |
| US-9199102-B2 | A3 adenosine receptor ligands for modulation of pigmentation | ORADIN PHARMACEUTICAL LTD. (IL) | 2015-12-01 | — | — | US | disclosed |
| WO-2012125400-A1 | COMPOSITIONS AND METHODS USING ADENOSINE A3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY EYE DISEASES | ACORN BIOMEDICAL, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120134945-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | ORADIN PHARMACEUTICAL LTD. (IL) | 2012-05-31 | — | — | US | disclosed |
| EP-2456419-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | Oradin Pharmaceutical Ltd. (IL) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011010306-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-01-27 | — | — | WO | disclosed |
| US-7199127-B2 | Purine nucleosides | UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-04-03 | — | — | US | disclosed |
| US-20050256143-A1 | Purin-9-yl-tetrahydrothiophene-3,4-diols; anticarcinogenic agents selective to A3 adenosine receptors; breast cancer | Government of the United States of America, repres ented by The Secretary, Department of Health and (US) | 2005-11-17 | — | — | US | disclosed |
| EP-1578758-A2 | PURINE NUCLEOSIDES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004038006-A2 | PURINE NUCLEOSIDES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256143-A1 | Purin-9-yl-tetrahydrothiophene-3,4-diols; anticarcinogenic agents selective to A3 adenosine receptors; breast cancer | ADORA3, P2RX3, P2RY1 | ADORA3 1/4885ADORA1 5/4885ADORA2A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.